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Abstract
Objective: The aim of this study was to evaluate the response of treatment of central giant cell lesion to intral-
esional corticosteroid injections.
Study Design: Review of articles indexed in PubMed on the topic between the years 1988 and 2011, and develop-
ment of a descriptive meta-analysis of the results. 
Results: Sample of 41 patients primarily treated with intralesional corticosteroid injections was obtained, with a 
male female ratio of 1:0.95, being 23 aggressive and 18 non-aggressive central giant cell lesions. Triamcinolone 
acetonide and triamcinolone hexacetonide were the drugs used, and 78.0% cases were considered as good result, 
14.6% were considered as moderate response and 7.3% were considered as negative result to treatment. Consider-
ing the aggressiveness, 88.9% of non-aggressive lesions presented a good response to treatment, in aggressive 
central giant cell lesions, 69.6% presented a good response to intralesional corticosteroid injections.
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Conclusion: In view of the results analyzed, intralesional corticosteroid injections could be considered as first treat-
ment option for central giant cell lesion.
Key words: Central giant cell lesion, corticosteroids injections, triamcinolone hexacetonide, triamcinolone acetonide.
Introduction
Central giant cell lesion (CGCL) is an uncommon type 
of benign jaw lesion that can be classified as aggres-
sive or non-aggressive (1,2). CGCL is more common 
in females (3-6), with a female/male ratio of 1.3:1 (7). 
This lesion can occur at all ages, but most cases are di-
agnosed in the second and third decades of life (3,7). 
The mandible is usually more affected than the max-
illa, with a mandible/maxilla incidence ratio of 2:1 (7). 
In radiographic analyses, CGCL may range from small 
apical lesions to large destructive multilocular radiolu-
cencies involving large areas of the jaws (7). 
Chuong et al. (2) first described aggressive and non-ag-
gressive CGCL. The former is characterized by one or 
more of the following: pain, paresthesia, root resorption, 
rapid growth, cortical perforation, and a high recurrence 
rate. Non-aggressive lesions present with slower growth 
and without cortical perforation or tooth resorption. Ag-
gressive lesions are usually larger and more frequently 
produce swelling (2). The pathogenesis of CGCL has 
yet to be elucidated.
Surgery is currently the most common proposed 
treatment for CGCL in the literature (5,6,8,9); surgi-
cal treatment methods range from simple curettage to 
aggressive en-bloc resection (4-6,10), which can lead 
to significant facial disfiguration. Intralesional corti-
costeroid injections are increasingly being used in the 
clinic, and some reports have shown excellent results. 
Intralesional corticosteroid injections can avoid ex-
tensive mutilating surgeries and successfully manage 
CGCL; the injections can be used alone or in combina-
tion with other treatment options, such as calcitonin 
or surgery (11). As most of the published articles on 
intralesional corticosteroid injections are case reports, 
the literature lacks data about this treatment modality. 
The aim of this study was to perform a meta-analytic 
study of intralesional corticosteroid injections for the 
treatment of CGCL.
Material and Methods
The articles referenced in the bibliography were col-
lected through a search of PubMed, using the follow-
ing keywords: central giant cell granuloma, central gi-
ant cell lesion, and intralesional corticosteroid. Study 
articles and case report articles were selected. Case 
reports were included, as only one research article has 
been published on this topic. The time parameters of the 
search were set between 1988 and 2011. Additionally, 
the report by Terry and Jacoway (12) was included in 
this review, as this was the first report to document int-
ralesional corticosteroid treatment for CGCL. The data 
were grouped into tables 1,2,3.
The inclusion criteria were as follows: articles pub-
lished between the years 1988 and 2011 and cases using 
intralesional corticosteroid injections as the first choice 
for treatment of CGCL. The following exclusion criteria 
were used: studies that included reports on peripheral 
giant cell lesion and those that used a combination treat-
ment of intralesional corticosteroids with other treat-
ment methods, such as calcitonin or surgery, as the first 
therapeutic choice. Fourteen articles that met the inclu-
sion criteria were selected. Of the articles selected, one 
was a research article, and thirteen were case reports.
The data obtained were analyzed for the following vari-
ables: number of cases, gender, mean age, location, ag-
gressiveness of CGCL, drug and protocol used, whether 
any additional procedures were necessary, result of the 
treatment and follow-up. The aggressiveness of CGCL 
was defined as proposed by Chuong at al. (2) using 
data available from the articles. Non-aggressive lesions 
were those that presented as slow growing and without 
symptoms, cortical perforation, or root resorption. Ag-
gressive lesions were those associated with pain, rapid 
growth, cortical perforation, root resorption, or a large 
size. Treatment results were analyzed as proposed by 
Nogueira et al. (13) using a four-item scoring system: A 
score of 1 indicated stabilization or regression in lesion 
size, as evaluated by the clinical aspect of the lesion and 
follow-up radiographs. A score of 2 represented the ab-
sence of symptoms. A score of 3 indicated an increased 
radio-opacity in the radiographs, representing peripher-
al and/or central calcification of the lesion. A score of 4 
indicated an increasing difficulty in a solution diffusing 
into the lesion upon multiple applications. When a case 
was positive for all four scores, the response was clas-
sified as good, two or three scores as moderate, and one 
or zero scores implied a negative response to the treat-
ment. If a case report did not indicate that the lesion was 
increasing in size or that the symptoms had not been 
controlled, these items were considered to have not hap-
pened, and the scores 1 and 2 were given to the report.
Results
The search resulted in a total of 14 articles, with 13 case 
or series reports (12,14-25) and one research article 
(13). A sample of 41 patients was obtained (20 males 
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and 21 females), with a female/male ratio of 1:0.95. The 
average age was 15.9 years; for aggressive lesions, the 
average age was 13.9 years, and for non-aggressive le-
sions, the average age was 18.3 years old. Twelve le-
sions were in the maxilla and 29 in the mandible, with a 
maxilla:mandible ratio of 1:2.4. According to the crite-
ria defined by Chuong et al.(2) 23 lesions were classified 
as aggressive CGCL and 18 lesions as non-aggressive. 
Triamcinolone acetonide (10 mg/ml or 40 mg/ml) and 
triamcinolone hexacetonide (20 mg/ml) were the adopt-
ed drugs, but one case report did not indicate the type 
of corticosteroid used (20). The drugs were always di-
luted with an anesthetic solution of marcaine, lidocaine 
or bupivacaine in equal parts. A 2-ml dose of this solu-
tion for every 2 cm of radiolucency was the most cited 
dosage, but a dosage of 1 ml for every 1 cm3 was also 
reported. The most frequently used protocol was a regi-
men of 6 weekly injections, but a biweekly protocol was 
also described, and in one patient, 20 injections were 
given. According to the criteria previously defined by 
Nogueira et al. (13) in 2010, 32 (78.0%) cases were con-
sidered good results, 6 (14.6%) were considered moder-
ate responses and 3 (7.3%) showed negative results to 
treatment (Data shown in tables 1,2,3).
Discussion
Surgery is the most common treatment of choice for 
CGCLs, and the extent of surgery ranges from curettage 
with or without adjuvant therapy, such as cryosurgery, 
peripheral ostectomy and carnoy solution, to aggressive 
en bloc resection (6,10), resulting in varying degrees of 
deformity (4). Conservative curettage and enucleation 
can lead to high recurrence rates, whereas en bloc re-
section may sacrifice adjacent structures, thus requiring 
surgical reconstructive procedures to recover satisfac-
tory functional and esthetic results (2). As some cases of 
CGCL affect children and young adults, defects in the 
developing dentition and jaws are of great concern (13). 
Reconstructive and rehabilitative procedures, which 
usually require multiple hospitalizations, and the use of 
dental implants and prosthetic devices are very costly.
Several non-surgical methods have been proposed to 
treat CGCLs, including radiotherapy (26), systemic cal-
citonin (27-29), intralesional injection with corticoster-
oids (12-25) and systemic α interferon (30,31). Among 
these non-surgical treatment methods, intralesional 
corticosteroid injection has shown promising results 
and can lead to a complete resolution of the lesion or a 
significant reduction in size, allowing a more conserva-
tive surgery (12,13).
Body et al. (32) first reported the use of corticosteroids in 
the treatment of CGCL. In their report, the authors used 
dexamethasone to treat an aggressive recurrent case of 
CGCL, achieving a significant reduction in lesion size; 
however, complications resulted because a systemic 
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?
Authors Number of 
cases 
Gender Age (years) Site Additional 
treatment 
Results 
Terry and Jacoway 
(12) 1994 3
2 male; 1 
female 8, 9 and 19 3 in mandible None
3 good 
response
Rajeevan and 
Soumithran, (15) 
1998
1 1 Female 17 Mandible None Good response 
Khafif et al. (16) 
2001 1 Female 
36
Maxilla None Good response 
Kurtz et al. (17) 
2001
1 Female 10 Mandible
Second session 
Good response 
after two 
treatment 
session 
Carlos and Sedano 
(19) 2002 
2 1 male; 1 
Female 
2 and 6 1 maxilla; 1 
mandible
Curettage in one 
case 
Good response 
in one cases; 
moderate
response in one 
case 
Sezer et al. (21) 
2005 1 Male 11 Mandible None Good response 
Mohanty and 
Jhamb (22) 2009 2
1 male; 1 
Female 10 and 20 Mandible None Good response 
Wendt et al. (23) 
2009 1 Female 8 Maxilla None Good response 
Nogueira et al. (13) 
2010
10 5 male; 5 
female
Average: 15.2  5 in Maxilla; 5 in 
Mandible
4 osteoplasty; 2 
surgical resection; 1 
curettage 
5 good 
response; 3 
moderate
response; 2 
negative
response
Shirani et al. (25) 
2011 1 Female 13 Mandible Surgical resection Negative 
Total 23 cases 10 male; 13 
female
average: 13.9  9 in maxilla; 14 
in mandible 
4 cases underwent 
osteoplasty; 2 cases 
underwent
curettage; 3 cases 
underwent surgical 
resection 
16 good 
response; 4 
moderate
response; 3 
negative
response
Table 2. Characteristics of aggressive central giant cell lesion studied.
?
Authors Number of 
cases 
Gender Age (years) Site Additional 
treatment 
Results 
Terry and 
Jacoway (12) 
1994
1 1 male 12 1 in mandible 
Second session of 
treatment and 
curettage 
Moderate
response
Kermer et al. 
(14) 1994 
1 1 Male 40 Mandible
New CGCL or 
recidive? after 
14months treated 
with same 
protocol
Good
response
Adornato and 
Paticoff (18) 
2001
1 Female 10 Mandible None Good
response
Carlos and 
Sedano (19) 2002 2 2 male 31 and 34  
1 maxilla; 1 
mandible None
Good
response
Abdo et al. (20) 
2005 1 Female 14 Mandible None
Good
response
Nogueira et al. 
(13) 2010 
11 6 male; 5 
female
Average 
15.8
3 in Maxilla; 8 
in Mandible 
osteoplasty in 4 
cases; curettage in 
2 cases 
10 good 
response; 1 
moderate
response
Ferretti et al. 
(24) 2011 1 Female 16 Mandible None
Good
response
Total 18 cases 10 male; 8 
female
Average 
18.3
4 in maxilla; 
14 in mandible 
Osteoplasty in 4 
cases; curettage in 
3 cases; new 
injections in 2 
cases 
16 good 
response; 2 
moderate
response
Table 3. Characteristics of non-aggressive central giant cell lesions studied.
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corticosteroid was used. Consequently, the dose was 
reduced, and the lesion re-grew. Terry and Jacoway 
(12) first reported the use of intralesional corticoster-
oid injections in the treatment of CGCL. Intralesional 
injections are preferable because they can achieve an 
elevated and localized concentration in the tissue (12). 
In addition, the complications associated with systemic 
corticosteroid administration usually do not appear, as 
none of the articles included in this meta-analysis re-
ported complications related to the corticosteroids.
The drugs used for treatment included triamcinolone 
acetonide (10 mg/ml or 40 mg/ml) and triamcinolone 
hexacetonide (20 mg/ml); both showed similar effica-
cies. The injections were administered weekly or bi-
weekly. Nogueira et al. (13) proposed that using a more 
concentrated drug, such as triamcinolone hexacetonide 
20 mg/ml, may allow for a biweekly interval, facilitating 
a greater reactivity and radiographic perception of the 
increasing radio-opacity. Six injections were the most 
common treatment regimen, but cases with up to 20 in-
tralesional injections were reported (19). Triamcinolone 
is always diluted in equal parts with an anesthetic solu-
tion, and a dose of 2 ml for each 2 cm of radiolucency or 
1 ml for each cm3 of lesion is injected.
Although CGCL is more frequently diagnosed in female 
patients (3-6), data from the present study found an al-
most equal frequency; 51.22% of cases occurred in fe-
male and 48.8% in male patients. Similar to other reports 
(3-7), in young patients, CGCL occurred more often in 
the mandible. In imaging studies, CGCL appeared as an 
uniloculated or multiloculated expansive osteolytic le-
sion and was frequently associated with tooth displace-
ment (12,13,17,23-25). Root resorption was seen in some 
cases (12,13), as was cortical perforation (13,21,22,25); 
the later is better seen in computerized tomography (CT) 
scans. Microscopically, CGCL appeared as multinucle-
ated giant cells in a cellular background composed of 
mononucleated stromal cells with an ovoid or spindle-
shape, with hemorrhage foci (13,19,20,23,25). Two re-
ports performed microscopic exams after the treatment 
and revealed a reduced number or, in some cases, the 
complete absence of CGCL, surrounded by markedly 
fibrocollagenous stroma and showing reduced vascu-
larization (13,19).
According to the criteria defined by Chuong et al. (2), 
23 lesions were classified as aggressive and 18 as non-
aggressive. Aggressive lesions tended to affect younger 
patients compared with non-aggressive lesions, with an 
average age of 13.9 years for aggressive CGCL and 18.3 
years for non-aggressive lesions. According to the cri-
teria previously defined by Nogueira et al. (13), a good 
response to intralesional corticosteroid injections was 
seen in 78.0% of CGCL patients, and only 7.3% showed 
a negative result. Considering only aggressive lesions, 
69.6% of cases presented a good response to treatment, 
and 13.0% showed a negative result. In non-aggressive 
CGCL, an even better result was found, as 88.9% these 
patients presented a good response to treatment, and 
none presented a negative result. These are excellent 
results, and it must not be forgotten that in cases show-
ing a negative response to treatment, others treatment 
options are available. In fact, surgical resection was 
performed in all cases with a negative result (13,25). 
It has been previously described that CGCL contain 
glucocorticoid receptors in multinucleated giant cells 
and mononucleated stromal cells (33); this may be the 
reason why CGCL regresses upon corticosteroid treat-
ment. More recently, Nogueira et al. (34) showed that in 
cases with good response to intralesional corticosteroid 
injections, a higher expression of glucocorticoid recep-
tors were seen in multinucleated giant cells. Although 
in most cases intralesional injections were used alone, 
additional treatment may be necessary. Esthetic osteo-
plasty was performed in 9 cases in the present study. 
Curettage was performed in 5 cases, mainly to remove 
residual lesion tissue.
Altough the authors are aware of the limitations of 
meta-analytic studies, these data suggest that a non-
surgical, intralesional corticosteroid injection approach 
for CGCL could be provided as a first-line treatment op-
tion. This treatment can lead to complete resolution of 
the lesion, or it may lead to a significant reduction in 
lesion size, allowing for a more conservative surgical 
approach. Further controlled prospective studies should 
be incentivized to corroborate these results.
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